Identification of genetic biomarkers to determine blood concentration of therapeutic agents for inflammatory bowel disease.

Identification of genetic biomarkers to determine blood concentration of therapeutic agents for inflammatory bowel disease. - Genetic biomarkers to determine blood concentration of medication agents.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000010197

Enrollment

Registered

2013-03-10

Start date

2010-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

inflammatory bowel disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients with IBD whom blood examination is necessary for the control of condition. All of the patients who undertaken azathioprine or tacrolimus can be the subjects of this study.

Exclusion criteria

Exclusion criteria: The patients who refuse to be subjects of this study and are judged as unfitness for the subject of this study by attending physician.

Design outcomes

Primary

Measure	Time frame
The relationship between blood 6-TGN concentration and dose of azathioprine when IBD patients taking azathioprine visit the hospital	—

Secondary

Measure	Time frame
The relationship between blood 6-TGN concentration, white blood cell count, and MCV when IBD patients taking azathioprine visit the hospital	—

Countries

Japan

Contacts

Public ContactKazuhiko Uchiyama

Kyoto Prefectural University of Medicine Molecular Gastroenterology and Hepatology

k-uchi@koto.kpu-m.ac.jp075-723-6511

Outcome results